Download PDF
Klin Monbl Augenheilkd 2021; 238(01): 85-91
DOI: 10.1055/a-1264-7962
Klinische Studie

Interdisciplinary Surveillance of Ocular Melanomas: Experiences in a German Tertiary Centre

Article in several languages: English | deutsch
Joel M. Mor
1   Zentrum für Augenheilkunde, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Deutschland
,
Alexander C. Rokohl
1   Zentrum für Augenheilkunde, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Deutschland
,
Cornelia Mauch
2   Klinik und Poliklinik für Dermatologie, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Deutschland
,
Ludwig M. Heindl
1   Zentrum für Augenheilkunde, Universität zu Köln, Medizinische Fakultät und Uniklinik Köln, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background In contrast to cutaneous melanoma, there are no uniform guidelines regarding surveillance of ocular (uveal, conjunctival) melanomas. A consented standard operating procedure (SOP) by the “Netzwerk onkologische Spitzenzentren” Germany only exists for conjunctival melanoma but not for uveal melanoma. Surveillance is partially based on German S3-guidelines for cutaneous melanoma and is carried out by oncologic centres in a multidisciplinary approach. This study aims to evaluate patientsʼ adherence to surveillance programs and whether surveillance recommendations (examinations, intervals) can be realised.

Methods Retrospective analysis of all ocular melanoma patients overseen at the University Hospital of Cologne between 2008 and 2019. The study evaluates rates of successful patient integration into a standardized surveillance program and patientsʼ surveillance adherence, subject to age, gender, primary therapy and tumour entity, respectively.

Results 99 patients were included (56 female, 43 male), 83 of which had uveal melanomas and 16 conjunctival melanomas. Mean follow-up was 59 months. 81% of patients were integrated into a surveillance program. Surveillance was performed according to published recommendations in 78%. 13% of patients dropped out of the surveillance program after a mean period of 38 months.

Conclusions Our data show a growing number of patients in standardized surveillance. However, there are still gaps. There is a need for guidelines specifically designed for ocular melanomas, allowing centres to offer patients an individualized approach.

Key words

ocular tumours - conjunctival melanoma - uveal melanoma - SOP - surveillance


Publication History

Received: 26 March 2020

Accepted: 11 September 2020

Article published online:
26 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References/Literatur

  • 1 Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma V. Twelve-year mortality rates and prognostic factors. COMS Report No. 28. Arch Ophthalmol 2006; 124: 1684-1693
    CrossrefPubMedGoogle Scholar
  • 2 Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology 1996; 103: 2017-2027
    CrossrefPubMedGoogle Scholar
  • 3 Mor JM, Koch KR, Kakkassery V. et al. [New treatment options for iridociliary tumors]. Ophthalmologe 2019; 116: 332-339
    CrossrefPubMedGoogle Scholar
  • 4 Mor JM, Semrau R, Baus W. et al. [CyberKnife®: new treatment option for uveal melanoma]. Ophthalmologe 2018; 115: 302-308
    CrossrefPubMedGoogle Scholar
  • 5 Heindl LM, Koch KR, Schlaak M. et al. [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma]. Ophthalmologe 2015; 112: 907-911
    CrossrefPubMedGoogle Scholar
  • 6 Mor JM, Heindl LM. Systemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma. Ocul Oncol Pathol 2017; 3: 133-141
    CrossrefPubMedGoogle Scholar
  • 7 Herold TR, Hintschich C. Interferon α for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol 2009; 248: 111-115
    CrossrefPubMedGoogle Scholar
  • 8 Russell HC, Chadha V, Lockington D. et al. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br J Ophthalmol 2010; 94: 1316-1321
    CrossrefPubMedGoogle Scholar
  • 9 Westekemper H, Meller D, Darawsha R. et al. [Operative therapy and irradiation of conjunctival melanoma]. Ophthalmologe 2015; 112: 899-900 902–906
    CrossrefPubMedGoogle Scholar
  • 10 Glossmann JP, Skoetz N, Starbatty B. et al. [Conjunctival melanoma: Standard operating procedures in diagnosis, treatment and follow-up care]. Ophthalmologe 2018; 115: 489-498
    CrossrefPubMedGoogle Scholar
  • 11 Shields CL, Shields JA, Gündüz K. et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 2000; 118: 1497-1507
    CrossrefPubMedGoogle Scholar
  • 12 Esmaeli B, Wang X, Youssef A. et al. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001; 108: 2101-2105
    CrossrefPubMedGoogle Scholar
  • 13 Shields CL, Kaliki S, Furuta M. et al. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8033 cases. Retina 2012; 32: 1363-1372
    CrossrefPubMedGoogle Scholar
  • 14 Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-4659
    CrossrefPubMedGoogle Scholar
  • 15 Refaian N, Schlereth SL, Koch KR. et al. Comparing the hem- and lymphangiogenic profile of conjunctival and uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2015; 56: 5691-5697
    CrossrefPubMedGoogle Scholar
  • 16 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology 2011; 118: 2351-2360
    CrossrefPubMedGoogle Scholar
  • 17 Heindl LM, Hofmann-Rummelt C, Adler W. et al. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci 2011; 52: 7074-7083
    CrossrefPubMedGoogle Scholar
  • 18 Francis JH, Patel SP, Gombos DS. et al. Surveillance options for patients with uveal melanoma following definitive management. Am Soc Clin Oncol Educ Book 2013; 382-387 doi:10.14694/EdBook_AM.2013.33.382
    CrossrefPubMedGoogle Scholar
  • 19 Diener-West M, Reynolds SM, Agugliaro DJ. et al. Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23. J Clin Oncol 2004; 22: 2438-2444
    CrossrefPubMedGoogle Scholar
  • 20 Dogrusöz M, Jager MJ, Damato B. Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol (Phila) 2017; 6: 186-196
    PubMedGoogle Scholar
  • 21 Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol 2015; 63: 93-102
    CrossrefPubMedGoogle Scholar
  • 22 Nathan P, Cohen V, Coupland S. et al. Uveal melanoma UK national guidelines. Eur J Cancer 2015; 51: 2404-2412
    CrossrefPubMedGoogle Scholar
  • 23 Onken MD, Worley LA, Ehlers JP. et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-7209
    CrossrefPubMedGoogle Scholar
  • 24 Cook SA, Damato B, Marshall E. et al. Reconciling the principle of patient autonomy with the practice of informed consent: decision-making about prognostication in uveal melanoma. Health Expect 2011; 14: 383-396
    CrossrefPubMedGoogle Scholar
  • 25 Marshall E, Romaniuk C, Ghaneh P. et al. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients. Br J Ophthalmol 2013; 97: 159-163
    CrossrefPubMedGoogle Scholar
  • 26 Afshar AR, Deiner M, Allen G. et al. The patientʼs experience of ocular melanoma in the US: A survey of the ocular melanoma foundation. Ocul Oncol Pathol 2018; 4: 280-290
    CrossrefPubMedGoogle Scholar
  • 27 Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127
    CrossrefPubMedGoogle Scholar
  • 28 Augsburger JJ, Corrêa ZM, Trichopoulos N. Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival. Am J Ophthalmol 2011; 152: 5-9.e1
    CrossrefPubMedGoogle Scholar
  • 29 Feinstein EG, Marr BP, Winston CB. et al. Hepatic abnormalities identified on abdominal computed tomography at diagnosis of uveal melanoma. Arch Ophthalmol 2010; 128: 319-323
    CrossrefPubMedGoogle Scholar
  • 30 Antoch G, Vogt FM, Freudenberg LS. et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199-3206
    CrossrefPubMedGoogle Scholar
  • 31 Algazi AP, Tsai KK, Shoushtari AN. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122: 3344-3353
    CrossrefPubMedGoogle Scholar
  • 32 Sagiv O, Thakar SD, Kandl TJ. et al. Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol 2018; 136: 1236-1241
    CrossrefPubMedGoogle Scholar
  • 33 Kiyohara T, Tanimura H, Miyamoto M. et al. Two cases of BRAF-mutated, bulbar conjunctival melanoma, and review of the published literature. Clin Exp Dermatol 2020; 45: 207-211 doi:10.1111/ced.14060
    CrossrefPubMedGoogle Scholar
  • 34 Boudousquie C, Bossi G, Hurst JM. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology 2017; 152: 425-438
    CrossrefPubMedGoogle Scholar
  • 35 Heindl LM, Koch KR, Hermann MM. et al. Block excision of iridociliary tumors enables molecular profiling and immune vaccination. Ophthalmology 2017; 124: 268-270
    CrossrefPubMedGoogle Scholar
  • 36 Shields CL, Dalvin LA, Vichitvejpaisal P. et al. Prognostication of uveal melanoma is simple and highly predictive using The Cancer Genome Atlas (TCGA) classification: A review. Indian J Ophthalmol 2019; 67: 1959-1963
    CrossrefPubMedGoogle Scholar